Clinical Trial

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Study acronym: CATT1
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Protocol Amendment History 6 changes
critical Enrollment closed, study ongoing 2026-07-29
notable Trial sites reduced: 61 -> 52 locations 2026-07-29
notable Primary completion pushed: 2026-09 -> 2027-04 2026-07-29
minor Completion pushed: 2026-10 -> 2027-05 2026-07-29
notable Trial sites expanded: 58 -> 61 locations 2026-06-03
notable Trial sites expanded: 51 -> 58 locations 2026-04-25
Trial Details
NCT Number NCT06334133
Lead Sponsor vTv Therapeutics
Conditions Diabetes Mellitus, Type 1
Enrollment 150 participants
Start Date 2024-06-14
Primary Completion 2027-04 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-28